212 related articles for article (PubMed ID: 527342)
21. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
[TBL] [Abstract][Full Text] [Related]
22. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
[TBL] [Abstract][Full Text] [Related]
23. Effect of a once weekly oral contraceptive upon gonadotrophin and gonadal steroid levels.
Tredway DR; Mishell DR
Contraception; 1974 Aug; 10(2):159-69. PubMed ID: 4418460
[TBL] [Abstract][Full Text] [Related]
24. The effect of progestin R 2323 released from vaginal rings on ovarian function.
Johansson ED; Luukkainen T; Vartiainen E; Victor A
Contraception; 1975 Sep; 12(3):299-307. PubMed ID: 1164848
[TBL] [Abstract][Full Text] [Related]
25. Effect of norethindrone acetate released from a single silastic implant on serum FSH, LH, progesterone and estradiol-17beta of women during first eight months of treatment.
Rahman SA; Jha P; Laumas V; Jain AK; Dileepkumar ; Takkar D; Hingorani V; Laumas KR
Contraception; 1977 Nov; 16(5):487-97. PubMed ID: 590011
[TBL] [Abstract][Full Text] [Related]
26. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
[TBL] [Abstract][Full Text] [Related]
27. Pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
[TBL] [Abstract][Full Text] [Related]
28. Effect of daily administration of 0.5 mg. of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle.
Saunders DM; Marcus SL; Saxena BB; Beling CG; Connell EB
Fertil Steril; 1971 May; 22(5):332-44. PubMed ID: 4102481
[TBL] [Abstract][Full Text] [Related]
29. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
Nilsson CG; Lähteenmäki P; Luukkainen T
Contraception; 1980 Mar; 21(3):225-33. PubMed ID: 6771090
[TBL] [Abstract][Full Text] [Related]
30. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
31. Ovulation inhibition by a new low-dose progestagen.
Viinikka L; Hirvonen E; Ylikorkala O; Nummi S; Virkkunen P; Ranta T; Alapiessa U; Vihko R
Contraception; 1977 Jul; 16(1):51-8. PubMed ID: 334460
[TBL] [Abstract][Full Text] [Related]
32. Pituitary and gonadal function during the use of norgestrelestradiol vaginal rings.
Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1978 Sep; 18(3):201-11. PubMed ID: 720065
[TBL] [Abstract][Full Text] [Related]
33. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
[TBL] [Abstract][Full Text] [Related]
34. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
Croxatto HB; Salvatierra AM; Romero C; Spitz IM
J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
[TBL] [Abstract][Full Text] [Related]
35. Ovulation inhibition with nafarelin acetate nasal administration for six months.
Brenner PF; Shoupe D; Mishell DR
Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
[TBL] [Abstract][Full Text] [Related]
36. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. III. Effect of preovulatory administration following the luteinizing hormone surge on ovarian steroidogenesis.
Ling WY; Wrixon W; Acorn T; Wilson E; Collins J
Fertil Steril; 1983 Nov; 40(5):631-6. PubMed ID: 6628707
[TBL] [Abstract][Full Text] [Related]
37. Pituitary and ovarian responsiveness to a graded gonadotropin releasing factor stimulation test in women using a low-estrogen or a regular type of oral contraceptive.
Spellacy WN; Kalra PS; Buhi WC; Birk SA
Am J Obstet Gynecol; 1980 May; 137(1):109-15. PubMed ID: 6768295
[TBL] [Abstract][Full Text] [Related]
38. Plasma profile on pituitary gonadotropins and ovarian steroids in women during 17 alpha-acetoxy- 11 beta-methyl-19-nor-progesterone administration.
Pérez-Palacios G; Iramain C; Castañeda E; Rojo B; Long DW; Scaglia HE; Gual C
Contraception; 1975 Jul; 12(1):37-43. PubMed ID: 1139948
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
Nillius SJ; Bergquist C; Wide L
Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
[TBL] [Abstract][Full Text] [Related]
40. Investigation of Danazol as a contraceptive agent.
Wentz AC; Jones GS; Sapp KC
Contraception; 1976 May; 13(5):619-30. PubMed ID: 1261264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
